$HHS

Harte Hanks (HHS) Q2 Revenue Falls 14%

Harte Hanks ( NASDAQ:HHS ) , a marketing and customer experience solutions provider, released its results on August 7, 2025. The most important news from the release was a broad drop in GAAP revenues and profitability, with revenue ( GAAP ) and EBITDA declining sharply across all business ...

Original reporting
Motley Fool · JesterAI
Published Aug 8, 2025, 12:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2025, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Harte Hanks (HHS) Q2 Revenue Falls 14% — source image
Decision brief

The 30-second read

$HHSBearishMed
01

Why it matters

The revenue drop could signal broader industry headwinds or internal issues, affecting investor confidence.

02

Market read

The news is relevant for traders holding or considering HHS, especially in the short term, but has limited broader market implications.

03

What to watch

Potential for a sector rotation or broader market rally that could offset company-specific negatives.

Timing: Immediate, as the news is recent and impacts current trading sessions.

Background

Harte Hanks operates in marketing and customer experience solutions, with recent revenue declines indicating operational or market challenges.

Company-level read

Ticker impact

$HHSBearishHigh confidence
Context

Primary focus of the news, significant impact on stock performance expected.

Expected impact

Moderate decline in stock price over the short term, with potential for continued downside if trends persist.

Evidence & confidence

The revenue decline is broad across all business segments, signaling systemic issues that are likely to weigh on stock performance in the near term.

$HHSBearishMedium confidence
Context

Relevance score of 0.26224 indicates moderate impact; the news is specific to HHS, but overall industry impact is limited.

Expected impact

Potential short-term downward pressure; long-term impact depends on company's response and industry conditions.

Evidence & confidence

While the news is significant for HHS, its moderate relevance score suggests limited immediate impact on broader market indices or related stocks.

Market effects

Potential sector-wide caution if similar companies report declines.

Limited, as the news pertains to a U.S.-based company with no immediate regional implications.

Negligible, unless similar trends emerge across the industry globally.

Counterpoint

The revenue decline may be a temporary setback; the company could implement corrective measures leading to a recovery.

Key entities

  • Harte Hanks

    A provider of marketing and customer experience solutions.

Related articles

$HHSHighAI 9/10

Harte Hanks To Be Acquired By Star Equity For $38.4 Mln

Harte Hanks (HHS) and Star Equity Holdings (STRR) announced a merger in which Star Equity will acquire Harte Hanks for $5 per share, totaling about $38.4 million, about a 100% premium to Harte Hanks’ unaffected price, according to the companies. A 30-day go-shop runs until Sept. 13, with closing expected in 60 to 90 days. HHS was up 3.91% to $2.920 premarket.

$HHSHighAI 10/10

Harte Hanks, Inc.: Harte Hanks Enters Definitive Agreement to Be Acquired by Star Equity Holdings for $5.00 Per Share

Harte Hanks (NASDAQ:HHS) and Star Equity Holdings (NASDAQ:STRR) entered a definitive merger agreement under which Star Equity will acquire all Harte Hanks shares for $5.00 per share, about $38.4 million total equity value. Consideration is 50% cash and 50% Star Equity 10% preferred stock. Closing is expected in 60 to 90 days.

$HHSHighAI 9/10

Harte Hanks stock rises on $5 per share acquisition deal

Harte Hanks Inc (NASDAQ:HHS) shares rose 2.1% premarket after Star Equity Holdings Inc (NASDAQ:STRR) agreed to acquire HHS for $5.00 per share. The deal implies about $38.4M aggregate equity value, a 100% premium. HHS shareholders may take $5 cash or 0.50 shares of STRRP preferred. Board approved; expected close in 60-90 days.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.